Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Eluxadoline: Completed Phase III enrollment

Furiex completed enrollment in a 30-week, double-blind, placebo-controlled international Phase III trial evaluating 75 and 100 mg

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE